Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243123 | 0.94 | TRPV1 (0.45) | TRPV1P2RX7GALR3HTTRAB9A | |
| SCHEMBL2238868 | 0.93 | PARP1 (0.40) | TRPV1P2RX7GALR3HTTRAB9A | |
| SCHEMBL2243312 | 0.91 | ALDH1A1 (0.48) | TRPV1P2RX7GALR3HTTRAB9A | |
| SCHEMBL2243012 | 0.88 | P2RX3 (0.43) | TRPV1P2RX7SMN1; SMN2KCNQ2MAPT | |
| SCHEMBL2242730 | 0.87 | ROCK2 (0.42) | TRPV1P2RX7GALR3HTTRAB9A | |
| SCHEMBL2242765 | 0.86 | TRPV1 (0.49) | TRPV1HTTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL2242997 | 0.86 | TRPV1 (0.45) | TRPV1P2RX7 | |
| SCHEMBL2243003 | 0.86 | TRPV1 (0.45) | TRPV1P2RX7 | |
| SCHEMBL2240751 | 0.85 | MC4R (0.38) | P2RX7GALR3HTTRAB9ASMN1; SMN2 | |
| SCHEMBL2243238 | 0.80 | ALDH1A1 (0.51) | TRPV1P2RX7SMN1; SMN2KCNQ2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994324-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-09 | — | — | US | claimed |
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | claimed |
| US-7994324-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | HTR5A, HTR2C, HTR2B | TRPV1 486/4885P2RX7 466/4885GALR3 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.